OPTH (Optimi Health) – DD on a psychedelic drug manufacturer that’s already generating revenue

Optimi Health (Nasdaq: OPTH) is a Health Canada-licensed manufacturer of GMP-grade psilocybin and MDMA capsules. Most psychedelic stocks are pre-revenue and dependent on trials. Optimi already sells finished-dose product to clinics in Australia, and it uplisted to Nasdaq in May 2026.

What the company does

Optimi manufactures finished-dose psilocybin and MDMA capsules at two facilities in Princeton, British Columbia. It holds a Health Canada Drug Establishment Licence, Dealer's Licence and Precursor Licence. Together these allow it to manufacture, test, package and export controlled drug products.

Rather than being another drug developer, it's positioned as the supplier: the picks-and-shovels play on psychedelic medicine.

Why I'm watching it

\- Revenue today. It supplies psilocybin and MDMA to Australian clinics under the TGA Authorized Prescriber Scheme, with a long-term distribution agreement with Mind Medicine Australia.
\- International expansion. It completed its first psilocybin export to the UK to support a planned Phase 2 trial.
\- Clinical upside. It announced a Health Canada-authorized Phase 3 trial of MDMA-assisted therapy for PTSD, planned for 2027, with up to 100 veterans and frontline workers.
\- Vertically integrated. It manufactures in-house with no reliance on third-party contract manufacturers, so new dosage formats can be developed and scaled quickly.
\- Product range. Natural psilocybin extract, MDMA 40mg and 60mg capsules, and a microdose line at 1mg and 2mg for wellness channels.

\- US optionality. Potential US market access if psilocybin and MDMA are federally rescheduled.

Catalysts to watch

\- Clinical progress (UK Phase 2, Canada Phase 3)
\- Revenue growth from Australia
\- New international supply agreements
\- US rescheduling developments